Loading institutional data...
Loading institutional data...
Institutional ownership roughly stable: -0.35% change quarter-over-quarter.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
2/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: -273%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
EOD close · as of 2026-09-18
Where each multiple sits in its own 10-yr range · 5th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 10-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 38.4× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 59.6 | 89.9 | 44.6 | 38.6 | 39.5 | 36.1 | 24.1 | 31.6 |
| Gross Profit | 40.4 | 10.1 | 55.4 | 61.4 | 60.5 | 63.9 | 75.9 | 68.4 |
| R&D | 117.5 | 210.1 | 31.0 | 17.4 | 22.6 | 26.7 | 111.1 | 184.0 |
| SG&A | 329.0 | 508.0 | 41.5 | 65.4 | 125.4 | 87.0 | 349.7 | 739.9 |
| Operating Income | -406.2 | -708.0 | -110.2 | -425.6 | -412.4 | -177.3 | -391.7 | -3269.4 |
| Income Tax | 0.1 | 0.4 | -1.6 | -2.0 | -3.4 | 0.6 | 15.2 | — |
| Net Income | -410.7 | -721.6 | -191.4 | -464.3 | -411.2 | -131.2 | -563.3 | -3209.7 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on HIND: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest.
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-09-18
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $320K 100.0% | $257K 100.0% | $8.7M 100.0% | $11.2M 100.0% | $13.6M 100.0% | $11.3M 100.0% | $3.3M 100.0% | $9.1M 100.0% | $9.9M 100.0% | $3.4M 100.0% |
| Cost of Revenue | $101K 31.6% | $62K 24.1% | $3.1M 36.1% | $4.4M 39.5% | $5.3M 38.6% | $5.0M 44.6% | $3.0M 89.9% | $5.4M 59.6% | $4.8M 48.7% | $2.8M 82.8% |
| Gross Profit | $219K 68.4% | $195K 75.9% | $5.5M 63.9% | $6.8M 60.5% | $8.3M 61.4% | $6.3M 55.4% | $331K 10.1% | $3.7M 40.4% | $5.1M 51.3% | $584K 17.2% |
| Research & Development | $588K 184.0% | $285K 111.1% | $2.3M 26.7% | $2.5M 22.6% | $2.4M 17.4% | $3.5M 31.0% | $6.9M 210.1% | $10.7M 117.5% | $10.6M 107.4% | $9.9M 291.0% |
| Selling, General & Admin | $2.4M 739.9% | $899K 349.7% | $7.5M 87.0% | $14.1M 125.4% | $8.9M 65.4% | $4.7M 41.5% | $16.7M 508.0% | $29.9M 329.0% | $28.8M 290.8% | $10.2M 301.1% |
| Total Operating Expenses | $10.7M 3337.8% | $1.2M 467.5% | $20.9M 241.2% | $53.2M 472.9% | $66.2M 487.0% | $18.7M 165.7% | $23.6M 718.1% | $40.6M 446.6% | $39.5M 398.2% | $20.1M 592.1% |
| Operating Income | -$10.5M -3269.4% | -$1.0M -391.7% | -$15.4M -177.3% | -$46.4M -412.4% | -$57.9M -425.6% | -$12.5M -110.2% | -$23.2M -708.0% | -$37.0M -406.2% | -$34.4M -346.9% | -$19.5M -574.9% |
| Interest Expense | $147K 45.9% | $206K 80.2% | — | — | — | — | — | — | — | — |
| Other Income (Expense), net | -$25K -7.9% | -$441K -171.7% | $122K 1.4% | $11K 0.1% | — | -$411K -3.6% | -$61K -1.9% | -$189K -2.1% | -$239K -2.4% | -$19K -0.6% |
| Pretax Income | — | -$7.1M -2759.7% | -$11.3M -130.6% | -$46.6M -414.5% | -$63.4M -466.3% | -$21.8M -193.0% | — | — | — | — |
| Income Tax Expense | — | $39K 15.2% | $52K 0.6% | -$380K -3.4% | -$274K -2.0% | -$181K -1.6% | $14K 0.4% | $11K 0.1% | $10K 0.1% | $2K 0.1% |
| Net Income | -$10.3M -3209.7% | -$1.4M -563.3% | -$11.4M -131.2% | -$46.2M -411.2% | -$63.1M -464.3% | -$21.6M -191.4% | -$23.7M -721.6% | -$37.4M -410.7% | -$34.8M -350.7% | -$20.5M -603.2% |
| Per Share | ||||||||||
| EPS (Basic) | $-4.86 | $-6001.39 | $-110.87 | $-108.90 | $-288.97 | $-5.55 | — | — | — | — |
| EPS (Diluted) | $-4.86 | $-6001.39 | $-110.87 | $-108.90 | $-288.97 | $-5.55 | — | — | — | — |
| Weighted Avg Shares (Basic) | 2.2M | 241 | 103K | 424K | 219K | 3.9M | — | — | — | — |
| Weighted Avg Shares (Diluted) | 2.2M | 241 | 103K | 424K | 219K | 3.9M | — | — | — | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Top 9 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $829.3B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.0B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $466.9B | 111.8× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $367.5B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $341.5B | 28.5× | 19.8× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.6B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $245.6B | 36.7× | 31.7× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $207.8B | 27.1× | 17.8× | 5.7× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $186.3B | 22.1× | 20.3× | 6.3× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.6B | 27.6× | 19.3× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.2B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $149.7B | 41.9× | 30.9× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $139.7B | 50.0× | 38.4× | 13.9× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $129.1B | 33.2× | 28.3× | 10.8× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $128.3B | 18.2× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $117.9B | 24.7× | 12.5× | 3.2× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $112.9B | 63.9× | 11.3× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $105.2B | 32.8× | 18.1× | 4.2× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.0B | 22.8× | 16.1× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.1B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $90.7B | 16.3× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.1B | 18.9× | 19.6× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.5B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| HIND | $12M | — | — | 38.9× | 24.4% | 68.4% | -3210% | -273% | -273% | — | 9 |
Peers = companies sharing HIND's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.